NCT00978211View on ClinicalTrials.gov

DOTA-TOC in Metastasized Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

1,499

Participants

Timeline

Start Date

September 30, 1997

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions
Neuroendocrine Tumors
Interventions
DRUG

DOTA-TOC Treatment

"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment."

Trial Locations (1)

4031

University Hospital, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT00978211 - DOTA-TOC in Metastasized Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter